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DAWN MILLER, JERRY FLOERSCH & MARTHA SAJATOVIC
ABSTRACT
Aims: This article investigates the subjective experience of the process of
improvement and recovery from the point of view of persons diagnosed (accord-
ing to research diagnostic criteria) with schizophrenia and schizo-affective
disorders.
Methods: A community study of persons using psychiatric services was con-
ducted for a sample of ninety subjects taking atypical antipsychotic medications.
Sociodemographic data and clinical ratings were collected to complement
the qualitatively developed Subjective Experience of Medication Interview (SEMI),
which elicits narrative data on everyday activities, medication and treatment,
management of symptoms, expectations concerning recovery, stigma, and qual-
ity of life.
Results: Recovery was observed through: (1) relatively low ratings of psychiatri-
cally observed symptomatology through BPRS scores; (2) the subjective sense
among the majority (77.4%) of participants that taking medication plays a critical
role in managing symptoms and avoiding hospitalization; and (3) the subjective
sense articulated by the vast majority (80%) that they would recover from their
illness and that the quality of their lives would improve (70.6%).
Conclusion: The overall quality of improvement and recovery is best character-
ized as an incremental, yet definitively discernable, subjective process.
INTRODUCTION
A recent report from a commission on mental health (Commission on Mental Health, 2003,
p. 5) has deﬁned recovery as ‘the process in which people are able to live, work, learn, and
participate fully in their communities. For some individuals, recovery is the ability to live a
fulﬁlling and productive life despite a disability. For others, recovery implies the reduction
or complete remission of symptoms’. In a conceptual overview, Mueser and colleagues
(2002) note ﬁrst, that recovery has been conceived as a process, outcome, or both; and
second, that while illness management and recovery are intertwined, nearly all research on
services and treatment has been conﬁned to illness management.
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The conceptualization and assessment of recovery can be thought to fall along a conti-
nuum from more objectively to more subjectively based indicators of outcome (WHO,
1979; Lin & Kleinman, 1988; Warner, 1994; Torgalsboen & Rund, 1998; Davidson et al.,
2001; Harrison et al., 2001; Markowitz, 2001; Liberman et al., 2002; Noordsy, et al., 2002;
Spaniol et al., 2002; Turner-Crowson & Wallcraft, 2002; Hopper, 2004). Objective measures
typically reﬂect symptomatic and functional outcomes indexed as work and social relation-
ships whereas more subjectively oriented studies seek to shed light on qualitative dimensions
of processes and factors associated with recovery (Leﬀ & Vaughn, 1985; Karno et al., 1987;
Jenkins, 1988; Kleinman, 1988; Jenkins & Karno, 1992; Salokangas, 1997; Torgalsboen &
Rund, 1998; Frese, 2001; National Institute of Health (NIH), 2001; Ridgway, 2001; Liberman
et al., 2002; Noordsy et al., 2002; Spaniol et al., 2002; Davidson, 2003). While both objective
and subjective indicators are ideally are collected together, it is clear that systematic qualita-
tive studies of considerable sample size are vitally needed at this stage in the investigation of
recovery. Such studies are necessary to identify the various social and cultural contexts for
recovery in the community (Jenkins, 1997; WHO, 1998; Floersch, 2002;), to include the per-
spectives of patients/consumers, families, advocacy groups, and service providers (Davidson
& Strauss, 1992; Salokangas, 1997; Jenkins & Schumacher, 1999; Tohen 2000; Jacobson,
2001a, 2001b; Markowitz, 2001; Turner-Crowson & Wallcraft, 2002; Corring, 2002;
Meddings & Perkins, 2002).
In the last two decades, pharmacological treatment through ‘atypical’ antipsychotic medi-
cations has led to reduction of both symptoms and extrapyramidal eﬀects compared to con-
ventional medications (Awad & Hogan, 1994; Weiden et al. 1996; Andersson et al., 1998;
Rosenheck et al., 1998; Breier et al., 2000; Dinakar et al., 2002; Lieberman et al., 2003).
Andersson et al. summarize evidence that atypical drugs are used eﬃcaciously with pre-
viously treatment-refractory patients and recent onset patients such that ‘use of atypical anti-
psychotics as a ﬁrst line treatment may result in better long-term clinical outcome’
(Andersson et al., 1998). While use of atypical medications among treatment refractory
patients may be associated with symptom reduction and participation in psychosocial reha-
bilitation treatments in the case of clozapine (Rosenheck et al., 1998), these eﬀects have yet to
be demonstrated in the case of other atypicals. It may be that the atypical agents are asso-
ciated with greater patient satisfaction due to fewer extrapyramidal symptoms, reduced
relapse, and, perhaps cognitive functioning (Awad & Hogan, 1994; Weiden et al., 1996;
Andersson, Chakos, Mailman, et al., 1998; Rosenheck, et al., 1998; Breier et al., 2000; Lieber-
man et al., 2003). At present, the literature is unclear whether atypicals are better than con-
ventional antipsychotics (Velligan, et al., 2003).
Our research group aimed to investigate the subjective experience of improvement and
recovery processes as outlined by the U.S. Commission in social contexts of everyday life
in the community from the vantage point of persons taking atypical antipsychotic medica-
tions (Hogan & Awad, 1992; Budd et al., 1996; Cuﬀel et al., 1996). This paper serves as back-
ground to more fully anthropological analyses to follow.
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METHODS
Sample selection
The research project, ‘Subjective Experience and the Culture of Recovery with Atypical Anti-
psychotics’ (SEACORA), is a study of persons (N ¼ 90) with schizophrenia-related disorders
according to research diagnostic criteria. Data collection was carried out September 1999–
June 2002. All research participants were taking atypical antipsychotic medications, the
majority of whom had been designated as previously treatment refractory in relation to
other antipsychotic drugs; however, some subjects (N ¼ 6) were prescribed atypical anti-
psychotic drugs as their ﬁrst psychopharmacological treatment.
Subject selection criteria included:
(1) diagnosis of schizophrenia or schizo-aﬀective disorder assessed through the Structured
Clinical Interview for DSM-IV (SCID) (First et al., 2002);
(2) age 18–55;
(3) at least two years since ﬁrst psychotic symptoms;
(4) at least six months of treatment with an atypical antipsychotic;
(5) absence of co-morbid substance abuse or organic impairment; and
(6) clinical stability suﬃcient to provide informed consent and participate in interviews.
The complete rosters of two community mental health outpatient facilities in a metropolitan
area of the US were obtained. Subject eligibility was assessed by treating psychiatrists and
individual therapeutic managers to create a complete listing of all patients who met research
diagnostic criteria. From this complete listing, participants were then randomly sampled.
When individuals did not meet study criteria after administration of the SCID, or refusal
to participate, these individuals were replaced by the next person on an SPSS-generated
random sample listing until the desired sample (N ¼ 90) was obtained. Toward the end of
the recruitment process, an attempt was made to include subjects such that a balance
would be achieved by sex and ethnicity across the two participating clinical sites. From the
list of randomly selected subjects who met inclusion criteria (167 subjects), 90 (54%) of
those selected were included in the ﬁnal sample, with 46.7% of these subjects refusing
research participation. The overall high rate of refusal is not unusual (Covell et al., 2003)
for an American community out-patient sample such as this, with males (55.9%) signiﬁcantly
more likely than females (29.3%) to refuse participation (Fisher’s Exact, p < :001). Reasons
for non-participation included a general lack of interest in research (stating simply they
‘didn’t want to’) or a reluctance to provide time for interviews (due to work scheduling or
preferences to spend time otherwise). Given this, it is likely that those who did participate
in the study diﬀered insofar as they were more interested in research, sometimes stating
that they had an interest in cooperating with anything that might beneﬁt others (or them-
selves) in future. In this regard, the sample may be more cooperative, functional or likely
to have had a positive experience with medication or their clinical providers than those in
the group who declined research participation.
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Procedures
The subjective experience of schizophrenia was studied though ethnographic interviewing
and observations, and questionnaires. The primary qualitative interview developed for the
current study on the basis of prior research (Jenkins, 1997) was designed to obtain narrative
data using a semi-structured, open-ended anthropological interview guide, the Subjective
Experience of Medication Interview (SEMI). The SEMI inquires into the experience of
medication and treatment, living situation, everyday activities, illness management, social
relations, gender identity, stigma, and expectations concerning recovery and quality of life.
The duration of these interviews was generally 1.5–2 hours over 1–3 interview sessions.
The expanded 24 item Brief Psychiatric Ratings Scale (BPRS) for symptom severity (Overall
& Gorham, 1962), along with other procedures to include the Ratings of Medication Inﬂu-
ence (Weiden et al., 1994; the Scale for the Assessment of Negative Symptoms (SANS)
(Andreasen, 1989) and the Bem Sex Role Inventory (Bem, 1974), and ethnographic natura-
listic observations of clinic, community, and home settings.
The data in this article include the sociodemographic and clinical characteristics of the
sample and SEMI data for subjectively perceived improvement and recovery. All SEMI inter-
views were transcribed verbatim from audiotape and entered into a qualitative software pro-
gram, Atlas.ti (Scientiﬁc Software Development, 1997), to code and analyze qualitative data
systematically (Good, 1994; Luborsky, 1993).
Coding of improvement through medication
Subjectively improved status on the basis of medication was determined in response to the
following SEMI questions: ‘Did you take other medication before? What is the diﬀerence
between that medication and what you’re taking now?’ Responses to these questions were
coded in relation to the diﬀerence between previous and current medications. When no
response could be determined from these speciﬁc questions, transcripts were reviewed for
spontaneous statements of comparison between previous and current medication. Cases in
which no response could be determined were coded as missing data. All individual responses
were coded according to the following rules:
(1) has the subject been treated with older neuroleptic medication? If the subject has had
atypical antipsychotic medication as the only course of treatment, there is no basis for
comparison and that individual is not included in this assessment;
(2) if coded aﬃrmatively, does the subject articulate a diﬀerence between previous and
current (atypical) medication? If the subject does not articulate an improvement or
change between previous and current medication, this constitutes no improvement; and
(3) does the subject describe atypical antipsychotics as better than previous medications?
Responses to this question were coded as yes, no, or ambiguous. Responses were coded
as ambiguous in the case of contradiction, when a response was highly qualiﬁed, or a
‘don’t know’.
Inter-rater reliability was good ( ¼ :69) for the coding schema above. One pair of raters
independently coded 20 randomly selected responses.
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Coding of improvement through personal power and control
Subjectively perceived personal power and control was addressed in relation to the following
interview question: ‘Do you have any power or control over your illness?’ Responses were
coded aﬃrmatively or negatively. Qualiﬁed responses that indicated some degree of control
over illness were coded aﬃrmatively. Inter-rater reliability was very good ( ¼ :88) for the
coding schema above. One pair of raters independently coded 20 randomly selected
responses.
RESULTS
Descriptive sociodemographic and clinical characteristics
Table 1 presents sociodemographic characteristics (N ¼ 90). The sample consisted of 49
(54.4%) men and 41 (45.6%) women. The majority (77.8%) were Euro-American and
22.2% African-American. The mean age was 40.7 (SD ¼ 7:9). The mean number of years
of education was 13.0 (SD ¼ 1:9). On the basis of an independent-sample t-test, men
(M SD ¼ 13:4 2:2) had more years of education than women (M SD ¼ 12:6 1:6;
t ¼ 2:00, df ¼ 86:6, p < :05). While the vast majority (84.4% of sample overall) had never
married, signiﬁcantly more men (95.9%) than women (70.7%) had never married (Fisher’s
Exact, p < :01). Relatedly, while most (42.2%) lived with a relative or parent, more
women (19.5%) than men (2.0%) lived with a partner/spouse (Fisher’s Exact, p <.01). In
addition, 17.8% had children, with more women (36.6%) than men (2.0%) having children
(Fisher’s Exact, p < :001). Overall, 40% was working either half or full time. In addition
to these income producing activities, 29 (32.2%) were engaged in volunteer activities (e.g. a
nursing home), 10 (11.1%) in educational activities (e.g. college or vocational courses),
and 20 (22.2%) in caretaking of a family member. Besides the 6% of the sample who were
in marital situations, 20 (23.5%) were in a dating relationship, and approximately one-half
(55.1%) of participants report satisfaction in the domain of social relations with friends.
As calculated by the Hollingshead index of social status (Unpublished manuscript), there
was a full range of background by class. These social class designations were representative of
the clientele of the two mental health sites for subject recruitment. Although there were no
signiﬁcant diﬀerences in socioeconomic status by gender, more men (36.7%) than women
(22.0%) were in upper socioeconomic classes (Classes I–II). There were no signiﬁcant diﬀer-
ences in socioeconomic status by ethnicity.
Table 2 shows clinical characteristics. The majority (81.1%) were diagnosed with schizo-
phrenia, 18.9% diagnosed with schizo-aﬀective disorder. The mean age at onset was 20.6
(SD ¼ 7:3). As often found in the literature (Goldstein, 1988; Seeman, 1995), an independent-
sample t-test showed that women (M SD ¼ 22:6 9:1) had a later age of onset than men
(M S ¼ 18:9 4:9; t ¼ 2:34, df ¼ 88, p < :02). The mean years ill was 20.1 (SD ¼ 8:4).
The mean number of admissions was 7.0 (SD ¼ 7:0). The mean length of outpatient treat-
ment, deﬁned as the length of treatment at current clinical site, was 7.6 years (SD ¼ 4:5).
An independent-sample t-test showed that Euro-Americans (M SD ¼ 8:1 4:5) had been
in outpatient treatment signiﬁcantly longer than African-Americans (M SD ¼ 5:8 4:0;
t ¼ 2:0, df ¼ 88, p < :05). There were no other signiﬁcant diﬀerences by gender or ethnicity.
Themajority (56.7%)were taking clozapine as their current atypical antipsychoticmedication.
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The other subjects were taking risperidone (17.8%), olanzapine (16.7%), or other (8.9%)
atypical medications. The mean duration of treatment with atypical antipsychotics for the
sample overall was 6.9 years (SD 4:1). Duration of treatment with atypicals ranged from
a minimum of 6 months to a maximum of 15 years.
Finally, BPRS scores show relatively low levels of symptomatology in the sample overall.
Conﬁrmatory factor analysis suggests a ﬁve-factor structure in samples of persons with long-
standing schizophrenia, such as this one (Burger et al, 1997). Scores on each factor were
divided by the number of items constituting each variable to place all scores on the same
scale of measurement. The factors are thought disorder (ﬁve items to include grandiosity, hal-
lucinations, unusual thought content, conceptual disorganization, bizarre behavior), anxiety/
depression (ﬁve items to include somatic concerns, anxiety, depression, guilt, suicidality),
Table 1
Sociodemographic characteristics of SEACORA participants (N ¼ 90)
Number Percent (%)
Gender
Male 49 54.4
Ethnicity
Euro-American 70 77.8
African American 20 22.2
Mean age (SD) 40.7 (7.9)
Mean years education (SD) 13.0 (1.9)
Marital status
Single 76 84.4
Married/partner 5 5.6
Divorced/widowed/separated 9 10.0
Living situation*
Alone 23 25.6
Roommate 5 5.6
Group home 15 16.7
Relative/parent 38 42.2
Partner/spouse 9 10.0
Have children
Yes 16 17.8
Working situation*
Not working 54 60.0
Half time or less (< 20 hours) 20 22.2
Half to full-time (20þ hours) 16 17.8
Hollingshead 4-Factor SES**
Class I 8 8.9
Class II 19 21.1
Class III 39 43.3
Class IV 23 25.6
Class V 1 1.1
* Due to rounding, percent may not equal 100
** From highest (I) to lowest (V)
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activity (ﬁve items to include tension, excitement, mannerisms and posturing, distractibility,
motor hyperactivity), hostility/suspicion (three items to include hostility, suspiciousness,
uncooperativeness), and withdrawal (six items to include disorientation, blunted aﬀect, emo-
tional withdrawal, motor retardation, elevated mood, and self-neglect). The level of sympto-
matology in this sample was quite low; the ﬁve factor scores ranged from 1.23 (activity) to
2.09 (anxiety/depression). As depicted in Table 2, mean scores for BPRS factors were as
follows: thought disorder (M SD ¼ 1:9 :88); withdrawal (M SD ¼ 1:9 :54); anxiety/
depression (M SD ¼ 2:4 1:0); hostility/suspicion (M SD ¼ 1:7 :65); and activity
(M SD ¼ 1:2 :32). On the basis of an independent-sample t-test, men had signiﬁcantly
greater thought disorder (M SD ¼ 2:1 :95) than women (M SD ¼ 1:7 :75) (t ¼ 2:16,
df ¼ 86:9, p < :04).
Given the possibility of speciﬁc ﬁndings in relation to antipsychotic medications (Awad
& Hogan, 1994; Weiden et al., 1996; Andersson et al., 1998; Rosenheck et al., 1998), we
investigated whether any diﬀerences could be observed for subjects treated with clozapine
compared with all other atypical antipsychotics, and signiﬁcant diﬀerences were noted with
respect to symptomatology. Based on independent-sample t-tests, subjects taking clozapine
Table 2
Clinical characteristics of SEACORA participants (N ¼ 90)
Number Percent (%)*
Diagnosis
Schizophrenia 73 81.1
Schizo-aﬀective 17 18.9
Mean age at onset (SD) 20.6 (7.3)
Mean years ill (SD) 20.1 (8.4)
Admissions
Mean (SD) 7.0 (7.0)
Median 5.0
Range 50.0
Outpatient treatment **
Mean (SD) 7.6 (4.5)
Median 7.0
Range 20.0
Current atypical antipsychotic
Clozapine 51 56.7
Risperidone 16 17.8
Olanzapine 15 16.7
Other 8 8.9
BPRS Subscores M  SD
Thought disorder 1.9  .88
Withdrawal 1.9  .54
Anxiety/depression 2.4  1.0
Hostility/suspicion 1.7  .65
Activity 1.2  .32
* Due to rounding, percent may not equal 100
** Length of treatment at current clinical site
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had signiﬁcantly lower scores for three BPRS factors: individuals taking clozapine had signi-
ﬁcantly lower thought disorder scores (M SD ¼ 1:76 :80) than individuals not taking
clozapine (M SD ¼ 2:17 :94) (t ¼ 2:23, df ¼ 87, p < :03); individuals taking clozapine
had signiﬁcantly lower anxiety/depression scores (M SD ¼ 2:05 :86) than individuals not
taking clozapine (M SD ¼ 1:05 :17) (t ¼ 3:44, df ¼ 87, p < :002); individuals taking
clozapine had signiﬁcantly lower hostility/suspicion scores (M SD ¼ 1:45 :55) than
other atypicals (M SD ¼ 1:91 :69) (t ¼ 3:50, df ¼ 87, p < :002).
Improvement through medication
Table 3 illustrates that of the 84 participants taking atypicals after having taken older neuro-
leptics, 77.4% indicated improvement on atypicals, 10.7% indicated no improvement, and
8.3% were ambiguous. Of the six individuals who had received atypical antipsychotics as
their initial treatment and thus had no basis for comparison between older neuroleptics
and atypical antipsychotics, ﬁve (83.3%) indicated they felt the atypical medications were
helping. There were no signiﬁcant diﬀerences in reported improvement in relation to clinical
(including type of atypical) or sociodemographic characteristics. While the African-American
sub-sample is not large, there is a tendency within that group for African-Americans to be
slightly more likely to report improvement through medications relative to the Euro-
Americans.
Overall, participants did widely endorse their subjective sense of the critical role of medica-
tions in contributing to improvement. Indeed, it is clear that medication subjectively occupies
the most prominent role in the incremental process of recovery as illustrated in a narrative
that invokes metaphor to convey the subjective eﬀect of the medication as:
A mental dam that stops the ﬂow of schizophrenia . . . The most important thing is ﬁnding
the right medication that starts to interact with the illness. And it just takes a long time.
(quote from study participant)
Table 3
Improvement with changeover to atypical antipsychotic medications (N ¼ 81)*
No Improvement Ambiguous Improvement**
N % N % N %
All participants
Male (N ¼ 45)
Female (N ¼ 36)
9
6
3
11.1
13.3
8.3
7
2
5
8.6
4.4
13.9
65
37
28
80.3
82.2
77.8
Euro-American (N ¼ 64)
African-American (N ¼ 17)
8
1
12.5
5.9
7
0
10.9
0.0
49
16
76.6
94.1
Schizophremia (N ¼ 68)
Schizo-aﬀect (N ¼ 13)
8
1
11.8
7.7
5
2
7.4
15.4
55
10
80.9
76.9
* 84 subjects took atypical antipsychotics after switching from older neuroleptics. 3 (3.6%) responses insuﬃ-
cient to code. For subjects taking atypicals as initial medication (N ¼ 6), 5 reported symptom improvement vs.
pre-medicated states
** No signiﬁcant diﬀerences by sociodemographic or clinical characteristics
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This process of trying a series of medications until the current point of relative satisfaction
was typical since most had struggled with their illness for two decades (M SD ¼ 20:1 8:4).
In this context, a subjective sense of recovery is experienced relative to the severity of the ill-
ness at an earlier time in one’s life; an important narrative feature of recovery is to relativize
one’s condition now compared to a far worse situation in the past.
Improvement and side eﬀects
While the data clearly indicate that a majority (77.4%) of individuals in the sample subjec-
tively perceived improvement as a result of treatment with atypical antipsychotic medication,
90.8% of those reporting improvement also report one or more disturbing side eﬀects that
they attribute to atypicals. As depicted in Table 4, individuals reported their perception of
the most troubling side eﬀect resulting from treatment with atypical antipsychotic medica-
tion. The three most commonly reported side eﬀects perceived to be the worst in the sample
overall were weight gain (18.2%), drooling (17.0%), and tiredness/drowsiness (17.0%).
Patients taking clozapine (28.0%) were signiﬁcantly more likely than patients taking other
atypical antipsychotics (2.6%) to report drooling as their perceived most troubling side
eﬀect (Fisher’s Exact, p < :001). Quite noteworthy are reports of no troubling side eﬀects.
In fact, 19.3% of the sample declined to cite a ‘worst side eﬀect’. This observation supports
our sense that this table under-reports troubling side eﬀects perhaps in relation to (a) grati-
tude for meds for symptom control (b) relative to typical antipsychotics they had been taking,
they considered that they had relatively fewer troubling side eﬀects, and thus deemed atypi-
cals as ‘better’ in relation to improvement.
The fact that such an overwhelming majority report serious side eﬀects points to a crucial
dilemma of lived experience of the atypical medications, that is, while most persons in the
study are tenacious in their conviction of the necessity to take these medications to avoid
symptom exacerbation and hospitalization, they nonetheless evince considerable ambiva-
lence and contradiction surrounding this predicament. While the atypical antipsychotic
Table 4
Rank-order of most troubling side eﬀect
Overall
N ¼ 88 (%)
Cloz.
N ¼ 50 (%)
Other atyp.
N ¼ 38 (%)
Weight gain
Drooling
Tiredness/drowsiness
Tremors/stiﬀness
Sexual dysfunction
Anxiety/fear
Gastrointestinal
Blood draws
None
18.2
17.0
17.0
10.2
5.7
5.7
3.4
3.4
19.3
16.0
{28.0{
16.0
6.0
6.0
6.0
2.0
6.0
14.0
21.1
2.6
18.4
15.8
5.3
5.3
5.3
0.0
26.3
N < 90 due to non-response
{ Drooling reported signiﬁcantly more for clozapine patients (Fisher’s Exact,
p < :001)
May not equal 100% due to rounding; no sig. diﬀerences by sociodemographic or
clinical variables
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drugs are generally associated with a more benign adverse eﬀect proﬁle compared to the older
neuroleptic agents, other adverse eﬀects such as weight gain, hyperprolactinemia, glucose
dysregulation and prolonged QTc interval remain problematic for some patients (Mortimer,
2003). This is an important issue for an eﬀective recovery process to include attention to indi-
vidual perception of adverse eﬀects.
Improvement through personal power and control
Despite the subjective salience of medication in the recovery process, participants emphasized
that medication could not do all the ‘work of recovery’. Analysis of the narrative data sur-
rounding personal power and control (Table 5) revealed that 51.1% subjectively experienced
having the capacity or will to struggle against the eﬀects of illness. Individuals who felt they
had a cultural sense of ‘personal power and control’ in relation to the illness underscored that
while medications have allowed them to make great improvements in reducing illness symp-
toms, they needed not only to rely on medications but also to do personal ‘work’ as crucial to
improvement and recovery (Strauss & Carpenter, 1977; Davidson, 2003). The psychocultural
work required for recovery is evident in the following statement:
I don’t think it’s easy for anybody, you know. Somebody said it’s a full time job, you know,
living with it, and I agree with that. You have to be working at it all the time.
An example of the ‘work of recovery’ came in response to the interview question ‘What can’t
medications do?’, as reported by a participant concerned with individual eﬀort and the
doctor-patient relationship:
Well, you have to have a lot of responsibility for yourself, too, because there’s nobody there
watching you take it. And that tells you something – they know that they’re trusting you.
In this and other narrative SEMI materials obtained, the role of sustained personal eﬀort was
often inexorably linked to social engagement, that is, personal eﬀorts were contingent on
engagement in social relations.
Table 5
Personal power and control over illness (N ¼ 90)
N %*
All participants 46 51.1
Male
Females
28
18
57.1
43.9
Euro-American
African-American
36
10
51.4
50.0
Schizophrenia
Schizo-aﬀective
39
7
53.4
41.2
* No signiﬁcant diﬀerences by sociodemographic or clinical
characteristics
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Recovery as incremental process of improvement
Overall, subjectively perceived improvement and recovery in relation to the metaphor of
‘awakenings’ was endorsed by only a minority of the SEACORA sample, who likewise
noted that such states were transitory. In either case, nearly all participants agreed that illness
management and improvement were gradual processes. They acknowledged occasional
relapses and set-backs as inherent to this process. Nevertheless, when participants were
also asked whether they expected the course of their illness to get better, stay the same, or
get worse, the majority (80%) fully expected an improved course of illness. When asked
whether they expected their lives to get better, worse, or stay the same, a majority (70.6%)
likewise conveyed that they expected their lives to get better. The remainder expected their
illness to stay the same (14.1%) and that their lives would likewise similarly stay the same
(25.9%). Only a fraction expected their illness would actually get worse (5.9%) and that
their lives would deteriorate (3.5%).
Incremental recovery is deﬁned as a process of improvement occurring gradually, experi-
enced subjectively in temporal terms of days, months, and even years. An example of the sub-
jective sense of getting better on a daily basis through taking medication came in response to
the SEMI question, ‘Do you think you’re getting better?’
Oh, deﬁnitely. I think a day doesn’t go by without my getting a little bit better. That’s the
nice thing about Clozaril. You do improve over time, you know, if you continue to take it.
I take it religiously.
Another narrative example of the diﬃculty of recovery, particularly when compared to a pre-
viously severe and continuously present illness, is the following:
I’m doing much better than I was (before), yeah. Finally. It was a long time coming. It was
hard, hard as hell. I mean, I don’t expect hell to be that hard. You know, that tough to
stand. And it was just nonstop from the second I woke up to the second I went to bed.
So it was really a nightmare.
Taken together with expectable set-backs, this subjective process is not experienced as a
progression that necessarily proceeds in linear fashion. In sum, the overall quality of self-per-
ceived recovery can be characterized as a slow, incremental, but deﬁnitively discernable
subjective process of improvement and recovery.
DISCUSSION
Among this sample (N ¼ 90) of community residents taking atypical antipsychotic medica-
tions for schizophrenia-related conditions, the level of observed symptomatology was rela-
tively low compared with similarly constituted samples who were taking conventional
neuroleptics (Jenkins, 1997; Karno et al., 1987) and particularly when compared with parti-
cipants’ own subjective assessment of their symptom levels prior to taking atypical anti-
psychotic medications. This ﬁnding for improvement in symptomatology in relation to the
atypicals has been reported elsewhere on the basis of psychiatric ratings of symptomatology
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(Breier et al., 2000; Dinakar et al., 2002). However, this is the ﬁrst study to do so systemati-
cally utilizing a large community sample from the perspective of patients themselves based on
narrative data of subjective experience. Factors associated with relatively better course of ill-
ness (age of onset, schizo-aﬀective diagnosis, social functioning to include marriage, children,
and family residence) among women (Goldstein, 1988; Seeman, 1995) were likewise observed
in this study. The ﬁnding for lower BPRS scores on three factor scores among those taking
clozapine compared with all other atypicals may suggest that treatment-refractory patients’
symptomatic improvement is even more observable for those taking clozapine.
The observation that 40% worked in half or full time employment can be taken as an indi-
cator of improvement; however, the fact that the majority of the sample was not employed
may indicate either that most were actually unable to work in income-producing jobs or
that appropriate employment was not available to them. This latter possibility may be due
to ﬁnancial restrictions placed on persons working (who may forfeit disability and other
governmental assistance necessary to pay for prescribed medications). In addition, as
noted by several in the study, supportive employment that is geared to diverse levels of func-
tioning is often unavailable.
Analysis of narrative data reveals that participants’ experience of improvement was obser-
vable as an incremental yet deﬁnitively discernable subjective process. This incremental process
is one of improvement in both expected course of illness and own’s life more generally.
Similarly noteworthy was the small fraction who expected their illness would actually get
worse or that their lives would deteriorate. This is a striking ﬁnding in a sample of previously
severely ill persons, calling into question early clinical characterizations of schizophrenia as
invariably chronic and degenerative (Kraepelin, 1919). These expectations for improvement
are likely due in part to the perceived eﬃcacy of the atypical medications, on the one hand,
and to American cultural and ethnopsychological orientations that highlight optimism and
forward-moving progression of the individual, on the other (Shweder & Bourne, 1984;
Chang, 2001). The results must be interpreted also, however, in relation to relatively ‘advan-
taged’ persons compared to their counterparts with fewer economic, social, and treatment
resources. In addition, this sample reported being fairly regular in taking medication and
might not be similar to those who either do not take medication regularly or have not had
as positive an experience relative to this sample. Within this data set, however, there were
no diﬀerences between the middle and upper class subjects and those of lower socioeconomic
status with respect to positive regard for their medication. Nevertheless, limitations of the
present study include the following:
(1) potentially limited application beyond Euro-American, African-American, poor social
resources, homelessness, or substance abuse;
(2) research subjects who agreed to participate may have had a better experience with medi-
cation and providers, leaving poorer responders understudied;
(3) while there is utility in comparing heterogeneous second-generation atypicals, the large
number of treatment-refractory patients taking clozapine in this sample may have had
distinctive illness histories;
(4) the limited involvement in psychotherapy and non-pharmacologic treatments may have
contributed to a subjective emphasis on medications; and
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(5) family perspectives not captured in the present study which focused rather on patients’
perspectives.
Given these limitations, our ﬁndings allow us to demonstrate that, from patients’ perspec-
tives, incremental improvement and recovery are subjectively discernable. This is signiﬁcant
given the history of psychiatry that has tended to conceptualize schizophrenia as an inher-
ently chronic, degenerative condition. Also, the incremental improvement was considered
by the patients to have been due primarily to the eﬀects of the atypical antipsychotic medica-
tions. While there were no signiﬁcant diﬀerences by gender or ethnicity in the extent to which
subjects considered that they had improved through atypical medications, it is noteworthy
that African-Americans tended to be somewhat more likely to report subjective improvement
relative to Euro-Americans (76.6% vs. 94.1%). This suggests the future relevance of investi-
gating further the subjective experience of medications in relation to ethnicity and social class.
The ﬁnding for improvement and recovery in relation to personal power and control was
split relatively evenly insofar as 51.1% aﬃrmed that they had personal power and control in
relation to the illness whereas 48.9% did not. This is a complex with various possibilities. For
example, one may consider that they have personal power and control conferred to them by
taking the medications or conversely that they have no personal power or control because
they are taking medications that have eﬀects independent of anything that they might
think or do. We are inclined to think that the cultural sense that one has no personal
power or control over the illness is problematic insofar as such a stance may discourage
active strategies for improvement and recovery (Deegan, 1988; Hogarty, 2002), resigning one-
self to the prospect of having a ‘broken brain’ about which one can do nothing, on the one
hand, yet alleviating unhelpful personal and familial guilt about etiology and course of illness,
on the other. Yet another critical consideration for interpretation of these ﬁndings is an
American culturally speciﬁc orientation that from a cross-cultural perspective might be
hypothesized as relatively ‘high’ in relation to the notion of ‘personal power and control’.
In other societies, religious and supernatural orientations might be expected to be vital to
the process of recovery and the idea that individuals would ﬁgure prominently into recovery
from illness might appear strange. A leading cultural theorist (Geertz, 1984) makes this point
broadly:
The Western conception of the person as a bounded, unique, more or less integrated moti-
vational and cognitive universe, a dynamic center of awareness, emotion, judgement, and
action organized into a distinctive whole and set contrastively both against other such
wholes and against a social and natural background is, however incorrigible it may seem
to us, a rather peculiar idea within the context of the world’s cultures. (p. 126)
Understanding the ﬁnding for the role of personal power and control in this American sample
as a cultural matter highlights the necessity of providing integrated care for schizophrenia to
combine culturally competent psychosocial and pharmacological interventions (Hogarty,
2002; Lenroot et al., 2003). While at present there are insuﬃcient studies available to state
with conﬁdence that the research participants in this sample are broadly representative of
those taking atypical antipsychotics, it is clear that other studies have likewise reported
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patients’ positive regard for atypicals in the case of clozapine despite adverse experiences
(Waserman & Criollo, 2000) and that a combined approach toward services and treatment
is in order (Hogarty, 2002; Mueser et al., 2002; Davidson, 2003; Lenroot et al., 2003).
CONCLUSION
In this community study of persons with schizophrenia and schizo-aﬀective disorders taking
atypical antipsychotics, the vast majority articulated their subjective sense of improvement
and recovery from their illness. The overall quality of improvement and recovery is best char-
acterized as an incremental, yet deﬁnitively discernable subjective process. The study of incre-
mental recovery thus constitutes a critical area for empirical investigation that takes into
account the subjective experience of processes of improvement according to systematically
collected narrative materials.
In this article, incremental processes of improvement were examined in relation to the sub-
jective sense of the critical role that taking medications plays in managing symptoms and
avoiding hospitalization. In sum, improvement and recovery from persistent and severe
mental disorders occur in the complex context of interlocking personal, cultural, social,
economic, and pharmacological eﬀects (Waserman & Criollo, 2000; Dinakar et al., 2002;
Lenroot et al., 2003; Jenkins & Barrett, 2004; Sajatovic et al., 2005). The complexity of
these relations as a matter of subjectivity suggests the theoretical and methodological require-
ment to specify these processes more fully through in-depth qualitative approaches that can
complement standardized scalar techniques of investigation (Davidson, 2003). Such a
complementary approach can contribute to the development of new strategies for treatment,
prevention, and community management of schizophrenia in line with the subjectively deter-
mined preferences and goals of persons struggling to recover and to live ordinary lives under
extraordinary circumstances (Jenkins, 2004).
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